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What is already known about this subject: 
 Therapeutic inhibition of the renin angiotensin system (RAS) has led to 
improvements in survival in patients with heart failure.  
 RAS inhibition has been associated with increased risk of acute kidney injury 
(AKI). 
 Patients at highest cardiovascular risk may be at higher risk of AKI due to 
additional comorbid factors. 
 
What this study adds: 
 We found risk factors for AKI in >60,000 patients prescribed RAS inhibitors 
were age, heart failure, diabetes, chronic kidney disease and comorbidity 
 Patients with greatest benefit from RAS inhibition are also at risk of AKI.  
 This association does not suggest causation; awareness of AKI is required in 
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Abstract 
Aims Therapy with angiotensin converting enzyme inhibitors (ACEi) and angiotensin 
receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes 
mellitus (DM) and chronic kidney disease (CKD). These agents have been associated 
with development of acute kidney injury (AKI) during intercurrent illness. Risk factors 
for AKI in patients prescribed ACEi/ARB therapy are not well described. 
Methods We the incidence of AKI in patients commencing ACEi/ARB during 2009-
2015 using anonymised patient records. Hospital-coded AKI was defined from hospital 
episode statistics; biochemical AKI was ascertained from laboratory data. Risk factors 
for biochemically detected and hospitalised AKI were investigated.  
Results Of 61,318 patients prescribed ACEi/ARB, with 132,885 person years (py) 
follow up, there were 1,070 hospitalisations with AKI as a diagnoses recorded and a 
total of 4,645 AKI events, including AKI episodes indicated by biochemical KDIGO-
based creatinine change criteria.  Incidence of any AKI event was 35.0 per 1000- py, 
hospital-coded AKI was 7.8 per 1000-py and biochemical AKI was 33.7 per 1000-py. 
Independent risk factors in a multivariable model for hospital-coded AKI events were 
age, male gender, HF, diabetes, cerebrovascular disease, lower estimated glomerular 
filtration rate, socioeconomic deprivation, diuretic or non-steroidal anti-inflammatory 
use (all p<0.001).  
Conclusion In patients prescribed ACEi/ARB, the highest risk of AKI is associated 
with conditions which are considered strong evidence-based indications for their 
prescription. Socio-economic status is an under-reported risk factor for AKI with these 
agents. Strategies targeted at prevention of AKI may be of benefit, such as enhanced 
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Introduction 
Therapeutic inhibition of the renin angiotensin system with angiotensin converting 
enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) drugs is a mainstay 
of therapy for conditions associated with increased cardiovascular risk including 
hypertension, heart failure (HF), diabetes mellitus (DM) and proteinuric chronic kidney 
disease (CKD). This approach has been established following landmark clinical trials 
demonstrating efficacy of these agents in improving outcomes[1-8].  
There is evidence that patients taking renin angiotensin system inhibitors 
(RASi) with ACEi/ARB in combination with non-steroidal anti-inflammatory drugs 
(NSAIDs) and diuretics are at increased risk of AKI[9, 10]. In addition, it is commonly 
reported that RASi are associated with acute kidney injury (AKI), particularly in the 
setting of impaired renal perfusion[9, 10]. A commonly described scenario for this is 
when a patient becomes dehydrated e.g. due to a diarrhoeal illness[11] and 
background RASi treatment leads to failure of regulation of angiotensin II-dependent 
glomerular perfusion and renal hypoperfusion leading to AKI. However, the degree to 
which RASi are causal for AKI in this setting are debated[12] . AKI in association with 
RASi therapy is common and the incidence is rising, either due to more widespread 
prescribing of these agents in patients at risk of AKI, or alternatively due to better 
awareness of AKI, including coding AKI as a diagnosis during hospitalisation[13, 14].  
AKI is common and when severe may be life threatening, often requiring 
hospitalisation and potentially acute dialysis. The overall mortality for acute kidney 
injury is high, with 1-year survival less than 50% even in mild AKI[15]. In patients who 
recover, it is common (but not invariable) for renal function not to return to the baseline 
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term studies show very poor survival up to one year after discharge[16]. Strategies 
that can identify people with high risk of AKI or poor outcomes are needed. 
AKI defined by the KDIGO criteria for diagnosis of AKI, based on small changes 
in creatinine, is associated with poor short and long term outcomes, irrespective of 
hospitalisation[18]. Electronic alerts (e-alerts) for biochemical AKI have been 
proposed as a mechanism for improving detection and management of AKI, although 
e-alerts need to be combined with education and clinical support to alter outcomes[19, 
20]. 
By linking demographic, clinical, prescribing and biochemical sources of patient 
data from both primary and secondary care, it is possible to ascertain the incidence 
of, and risk factors for AKI, including biochemical-only AKI detected by blood tests, 
and episodes of AKI requiring hospitalisation. The aim of this study, using novel 
linkage of electronic patient data in an area of social deprivation and high rates of 
cardiovascular disease[21], was to describe the incidence and risk factors for AKI 
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Methods 
Cohort 
Greater Glasgow and Clyde National Health Service (NHS) provides healthcare to a 
population of approximately 1.2million. The NHS Greater Glasgow and Clyde ‘Safe 
Haven’, is a secure environment whereby health data from different sources can be 
linked together and made available in de-identified form for analysis. It has been 
ethically approved by the ethics committee of NHS Greater Glasgow and Clyde. This 
specific project was approved Local Privacy Advisory Committee of the Safe Haven.  
All health episodes in Scotland are linked by the Community Health Index (CHI), a 
unique identifier for all patients. In this study, we used data related to NHS care, 
including patient records, prescribing, hospitalisations and laboratory testing. We 
defined patients included in the cohort as those incident users of RASi encashing at 
least one prescription for ACEi or ARB from the  prescription information system (PIS), 
which captures data of all ‘cashed’ prescriptions  in NHS Greater Glasgow and Clyde 
from Jan 2009-Dec 2015[22]. We excluded patients with prevalent use of RASi prior 
to 1/9/2009 and patients with a prior diagnosis of cancer (excluding non-melanoma 
skin cancer) at the time of commencement of RASi therapy. Patients entered the 
cohort at the date of their first prescription, and exited the cohort at death, at the last 
prescription date plus 30 days, to allow for a washout period, or at the end of the data 
extract from PIS. The makeup of the cohort is shown in Figure 1.  
Comorbidities at baseline were defined by the presence of a diagnosis of 
hypertension, heart failure (HF), diabetes mellitus (DM), cardiovascular disease 
(CVD), or cerebrovascular disease (CeVD), from general practitioner (GP) electronic 
records (termed ‘local enhanced service’ (LES)) data, as well as from ICD-10 codes 
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was calculated for all patients[23]. PIS records for all patients were used to identify 
additional treatment with diuretics (loop, thiazide and potassium sparing) and non-
steroidal anti-inflammatory drugs (NSAID). Patients were also classified as having 
chronic kidney disease (CKD) based on this being recorded by their GP within LES 
coding. We defined baseline kidney function as the mean estimated glomerular 
filtration rate (eGFR) calculated using the CKD-EPI formula in the year prior to cohort 
entry[24]. Serum creatinine measures were isotope dilution mass spectrometry 
aligned.   
The Scottish Government provide online calculators allowing use of patient 
postcode to generate divisions of socioeconomic deprivation, the Scottish Index of 
Multiple Deprivation (SIMD) (http://www.gov.scot/Topics/Statistics/SIMD). Using 
patient postcode, deprivation quintiles of deprivation status were calculated and 
categorised into most deprived (quintile 1) to least deprived (quintile 5). 
 
Definition of acute kidney injury (AKI) 
 Hospital-coded AKI was defined as a hospital admission with ICD-10 code N17 
in any diagnostic position on hospital discharge coding in the Scottish Morbidity 
Records 01 (SMR01). SMR01 collects data on all non-obstetric, non-psychiatric 
hospital discharges since 1968. Since 1989 SMR01 has been used to plan financial 
management of hospitals in order to ensure high completion rate. Internal audit of this 
data supports overall 89% accuracy for main condition diagnosis and similar or greater 
accuracy has been demonstrated in AKI in the United Kingdom[25, 26].  As a 
secondary event of interest, we captured the incidence, stage and severity of AKI 
episodes not associated with a hospitalisation episode, based on all creatinine 
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of exposure. These were categorised as ‘community-based AKI’, where the creatinine 
measure used to define AKI was taken from a blood sample which during a period 
which did not coincide with any hospital admission and ‘all AKI’ which encompassed 
hospital-coded  AKI, community-based AKI and ‘other AKI events’ i.e. AKI episodes 
occurring during a hospital admission but were not coded by hospital coding data on 
hospital discharge.  Biochemical AKI was defined using an algorithm aligned to the 
NHS e-alert AKI warning system currently implemented in NHS England for routine 
health care and as previously reported[27, 28]. AKI was diagnosed from the following 
criteria: 
1. Serum creatinine ≥1.5 times higher than the median of all creatinine values 8–
365 days ago 
2. Serum creatinine ≥1.5 times higher than the lowest creatinine within 7 days 
3. Serum creatinine >26 µmol/L higher than the lowest creatinine within 48 h 
 If one or more of these criteria were met, AKI was attributed to that date / 
measurement.  Our sources only resolved measurements to the level of date. When 
more than one value was recorded on a given day, the highest value was considered.  
Severity of AKI was based on the KDIGO definition applied to this algorithm[29].For 
every AKI identified above a staging was assigned per the following rules: 
 Stage 1: Serum creatinine ≥1.5 and < 2.0 times AKI baseline or >=26.0 µmol/l 
increase above AKI baseline 
 Stage 2: Serum creatinine >=2.0 and < 3.0 times AKI baseline 
 Stage 3: Serum creatinine 3.0 times AKI baseline or >=354 µmol/l increase 
above AKI baseline 
To avoid confounding by early changes in serum creatinine following instigation of 
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commencement of therapy. E-alerts were not used in the laboratory systems during 
the period of this study. We identified deaths and date of death by linkage to the 
National Records Scotland death certificates (NRS). 
 
Statistical analyses 
The primary outcome was defined as the incidence of first AKI – either biochemical 
AKI detected in the community, or hospitalisation for AKI. Patients who died during 
follow-up without experiencing an AKI event were censored at death. Kaplan Meier 
survival curves were generated for time to first AKI in relation to: age, sex, SIMD, 
eGFR, diuretics use at baseline, NSAID use at baseline, use of diuretics or NSAID at 
baseline, prescription groups at baseline and history of co-morbidities, namely: 
hypertension, heart failure, diabetes, CKD, cerebrovascular disease and Charlson 
Index of co-morbidities. Univariable Cox proportional hazard models were fitted to 
obtain estimates of the association between each covariate and incident AKI, reported 
as hazard ratios with 95% confidence intervals. The proportional hazards assumption 
was assessed using Schoenfeld residuals, and the assumption was not met for several 
variables in each model. However, visual inspection of Kaplan-Meier plots suggested 
that these deviations were quite subtle, and the hazard ratios may be interpreted as 
giving the average association over the follow-up period. 
Multivariable Cox regression models were fitted to further analyse the associations 
between covariates and incident AKI.  A manual backwards selection procedure was 
used, with all covariates (except for the Charlson Index excluded on the basis it is 
comprised of multiple co-morbidities being tested in the Cox model) considered in the 
starting model. Covariates were sequentially excluded based on the p-value, to obtain 
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level) to the model. All other predictors were categorical. No adjustments were made 
for multiple comparisons. All analyses were carried out using the statistical software 
package R[30]. 
Data avai ability 
The data that support the findings of this study are not publicly available due to privacy 
or ethical restrictions. Further information on the handling of electronic health record 





Demographics of cohort and Incidence of AKI 
Figure 1 summarises how the cohort of incident RASi users was generated. During 
the study period 61,318 patients were prescribed ACEi/ARB. The mean age of the 
cohort was 59.8 years (SD 13.9), and 51.9% were male. 3,302 (5.4%) had HF, 8,807 
(14.4%) had diabetes, and the mean eGFR was 86.1ml/min/1.73m2 (SD 18.2). There 
were 7993 deaths during follow-up. 
During a median follow up of 1.92 yrs there were 1,070 hospital-coded AKI events, 
and 4,483 biochemical AKI episodes. In total, 4,645 patients had at least one AKI 
event during 132,885 person years (py) of follow up. Hospital-coded AKI and 
biochemical AKI overlapped, but were not mutually exclusive, as 162 patients had a 
hospital-coded AKI, without confirmatory biochemistry, where the patient had no 
available baseline kidney function tests. The incidence of all AKI events was 35.0 per 
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Risk factors associated with AKI 
The patients at highest risk of AKI were those with most comorbidities. Data are 
presented on all AKI events in Table 1 (biochemical or hospital-coded AKI) as the 
overall pattern of risk factors associated with AKI were similar for both biochemical 
and hospital-coded AKI. Data on hospital-coded and biochemical AKI are presented 
separately in Tables 2 and 3. On univariable analyses of the association between 
baseline characteristics and incident AKI, the risk of AKI events increased with 
increasing age, socioeconomic deprivation (Figure 2), lower eGFR, diuretic use, heart 
failure, diabetes, a diagnosis of CKD, cerebrovascular disease, or increasing Charlson 
co-morbidity index. On univariable analysis there was no association with NSAID use 
in isolation (Table 2 and 3), and combined NSAID and diuretic use did not confer 
higher risk than diuretic use alone.  
Risk of AKI was highest in three distinct (though overlapping) groups. Patients with 
heart failure had an incidence of hospital-coded AKI of 29.4 per 1000-py and 
biochemical AKI of 122.4 per 1000-py. Similar figures were observed for patients with 
CKD with hospital-coded AKI incidence of 40.9 and biochemical AKI incidence of 
117.6 per 1000-py. Using Charlson index of 3 or more as a measure of greatest 
comorbidity identified a group of extremely high risk of both hospital-codeAKI and 
biochemical AKI (40.1 and 166.8 per 1000-py respectively, Tables 2 and 3).  
Using a multivariable Cox proportional hazards model, independent predictors of AKI 
were male gender, increasing age, increasing socioeconomic deprivation, diuretic use, 
NSAID use, history of heart failure, diabetes mellitus, eGFR, and history of 
cerebrovascular disease, as presented in Table 4. It is notable that male gender was 
associated with higher risk of AKI based on multivariable analysis, despite female 
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Discussion 
This is one of the first reports using routine clinical data to quantify risk factors for AKI 
in ACEi/ARB users. Patients with increasing comorbidity were at highest risk of AKI, 
with many conditions associated with increased risk of AKI, including HF, DM, and 
CKD – conditions where there is high grade evidence for using these drugs in 
accordance with national guidelines[31-33]. Patients concomitantly prescribed 
diuretics and NSAIDSs are at greater risk of AKI, as observed by others[9, 10]. 
Amongst incident patients prescribed ACEi/ARB medication, we found a similar rate 
of AKI episodes associated with a hospital admission to a previous cohort of 
ACEi/ARB users[14]. The incidence of biochemical AKI based on internationally 
recognised creatinine change criteria was approximately two-fold higher than has 
previously been reported for the general population in the Grampian region[34].  
 
Risk factors for both biochemical and hospital-coded AKI 
 The recognition of association of AKI with prescription of ACEi/ARB therapy in 
the setting of relative hypovolaemia is well established[11, 35]. However, using 
observational prescribing data combined with biochemical flagging and hospitalisation 
coding records for AKI, we identify patients at highest risk of AKI whilst prescribed 
these agents. Caution is required in interpreting any association between ACEi/ARB 
therapy and AKI as causal.  Recent studies using national primary care data did not 
demonstrate higher risk of hospitalisation with AKI overall, or following common 
infections including gastroenteritis, among users of ACEi/ARB compared to other 
antihypertensives[36]. Our data demonstrate that patients with the most compelling 
evidence-based indications for prescription of ACEi/ARB therapy are those at highest 
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where there are data from high quality randomised controlled trials (RCTs) suggesting 
benefit with these agents[1, 4-6, 8, 37, 38]. The evidence for benefits of ACEi are most 
compelling in patients with HF and reduced left ventricular ejection fraction[8, 38]. 
These agents are strongly recommended in the recent European Society of Cardiology 
(ESC) and American Heart Association (AHA) guidelines for management of HF[31, 
32]. However, despite our observation that AKI is common among those with HF on 
ACEi/ARB, AKI is described as ‘rare’ in HF patients in the ESC guidelines[31] and 
monitoring of renal function is seen as ‘good practice’ with no mention of AKI in the 
AHA guidelines[32]. Biochemically detected AKI events may represent natural 
fluctuations in serum creatinine occurring in patients with HF talking RASi often in 
combination with diuretic therapy. These changes may not represent ‘AKI’ with any 
intrinsic renal damage and may simply reflect changes in serum creatinine in the 
setting of haemodynamic perturbation as glomerular perfusion pressure responds to 
changes in hydration status. Nevertheless, greater rises in serum creatinine in patients 
requiring ACEi/ARB therapy highlights a group of patients at greater mortality risk 
during follow up[39]. Therefore, we would simply state that increased awareness of 
AKI in patients with HF is required and sensitivity is needed in interpreting AKI alerts 
in these patients. 
 There is evidence that these agents delay progression of proteinuric CKD 
and/or improve outcomes in patients with diabetes and albuminuria [5, 40]. These 
results suggest that the groups potentially deriving most benefit from these agents are 
at highest risk of being hospitalised with AKI, albeit in observational data with no 
control group. The clinical significance of these biochemically detected AKI events is 
unclear, and further studies are required to determine if these events confer any 
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subsequent CKD[41, 42], it is less clear whether subtler acute, transient declines in 
renal function lead to longer term renal risk.  
 
 
Multi-morbidity and AKI risk  
 In an ageing population with increasing comorbidity, the association of Charlson 
index and AKI episodes is concerning. These patients in this cohort were prescribed 
ACEi/ARBs based on evidence from randomised controlled trials, which were 
performed over 15 years ago. It should be recognised that in an aging society where 
multi-morbidity is more common, these RCTs may no longer be representative of 
many contemporary patients prescribed these agents. This was highlighted in a report 
from a similar population as our study, whereby 23.2% were classified as ‘multi-
morbid’[43]. On the other hand, undertreatment of multimorbid patients with HF is likely 
to be associated with poor survival. Multi-morbidity is common in patients from a 
socially deprived background[43]. We observed that social deprivation status was 
associated with increased AKI risk. Therefore, AKI risk in patients prescribed 
ACEi/ARB therapy is associated with a cluster of interrelated risk factors including 
number of comorbid conditions, concomitant therapy and socioeconomic deprivation.   
The optimal strategy to address the risk of AKI in the community in patients 
taking ACEi/ARB is unknown. General practitioners should be aware that that the most 
comorbid patients are most at risk and need close monitoring, particularly during acute 
illness. Initiatives to tackle this problem are currently being investigated such as ‘sick 
day rules’ where patients taking these drugs are advised to stop them during acute 
illness. This strategy requires resources for patient education and to date is not 
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Strengths and limitations of this study 
 The strength of these analyses include a large sample size, with excellent 
coverage of the population studied, avoiding sampling biases. The results 
demonstrating similar risk factors for hospital coded and biochemical AKI suggest that 
our analysis methods for assessing influence of comorbid variables were robust and 
give a consistent message.  We do not have a control group so the incidence of AKI 
in patients with these comorbid conditions not prescribed ACEi/ARB is unknown.  
Defining the most appropriate patients to study as a control group is challenging. There 
would be biases in selecting a group of patients commenced on an alternative class 
of antihypertensive medication such as calcium channel blockers. This has been 
explored in other studies with only small increases of AKI incidence with ACEi/ARB in 
comparison to patients exposed to antihypertensive regimes not including 
ACEi/ARB14. In the case of HF, it would be unusual not to be treated with ACEi/ARB 
therapy.   
 We acknowledge further limitations with these analyses. AKI without clinical 
symptoms may be diagnosed more frequently in patients having frequent blood 
samples (ascertainment bias). We are unaware of the indication for taking the blood 
sample leading to a record in the laboratory database.  The incidence of biochemical 
AKI in untested patients is unknowable. Whilst we use the term ‘hospital-coded AKI’, 
it is possible and indeed likely, that AKI was one of a number of diagnoses coded 
during a hospitalisation episode, rather than the sole diagnosis. There may be coding 
bias in either direction with hospital-coded AKI, where AKI is added as a diagnosis in 
the absence of biochemical evidence, or where AKI was present but not recorded as 
a diagnosis on hospital discharge. The incidence of biochemically diagnosed AKI was 
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of AKI, the use of an algorithm based on serum creatinine, may lead to a higher 
incidence of AKI related to how the algorithm diagnoses patients with an AKI event.  It 
is possible that some of the co-morbid conditions have not been coded in the health 
care records, leading to an under-reporting of the Charlson co-morbidity index.  This 
This can be seen with chronic kidney disease, where only 1989 subjects have been 
coded as having CKD by their general practitioner despite 4553 patients having a 
recorded GFR <59ml/min/m2 (which is likely to be consistent with CKD). 
 The prescribing records indicate that a patient collected a prescription, rather 
than took the prescribed medication. Although we describe CKD as an ‘indication’ for 
therapy, we do not have proteinuria data and therefore it is unclear how strong this 
indication was for ACEi/ARB therapy and or whether proteinuria alters risk of AKI.  
   
Conclusion 
  We describe associations of various clinical variables with increased risk of 
AKI in patients prescribed ACEi/ARB therapy. However, we do not describe these 
relationships as causal. The overwhelming evidence demonstrates that these 
medicines have heralded remarkable improvements in survival in patients with HF, in 
particular[8, 38] 
 We demonstrate that older patients with heart failure, diabetes, CKD, lower 
socioeconomic status and prior stroke are at highest risk of AKI, both hospital-coded 
and biochemically detected in the community. Biochemical AKI may serve as a risk 
marker for future adverse events. Further work is required to identify strategies to 
minimise risk of hospital-coded and/or biochemical AKI in patients receiving therapy 
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Table 1 Patient demographics and incidence of all AKI events with associated 
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Table 2  Patient demographics and incidence of hospitalised AKI events with 
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Table 3  Patient demographics and incidence of biochemical AKI events with 
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Table 4  Multivariable model for association between predictors and risk of any 
AKI event. Reference group for SIMD: SIMD 1(most deprived) 
 
  
 Hazard Ratio 95% C.I p-value 
Gender (Male) 




SIMD 5(Least deprived) 
Diuretics (Yes) 
NSAID (Yes) 
History of heart failure (Yes) 
eGFR at baseline (per 10 units increase) 
History of diabetes (Yes) 
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Figure 1 Flow diagram showing how cohort was generated for analysis from 
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Figure 2 Kaplan Meier curves for incidence of any AKI after first prescription of 
ACEi/ARB by SIMD Quintile 
 
